+7 (499) 340 10 14

Expense for Development is Justified

The first Russian generic pramipexole (INN pramipexole) for Parkinson disease has been approved.

The Ministry of Industry and Trade of the Russian Federation is the originator of the drug, which is included into the Vital and Essential Drug List.

Development of the first Russian generic drug pramipexole  within the Federal Target Program “Pharma-202” was sponsored out of the federal budget at 16 mln rubles. The market size, according to the INN data almost 30-fold exceeds expenses for generic development. Last year the market size was 448.01 mln Russian rubles.

Therefore, expenses for development of new import substitution products are well-justified.

LABMGMU LABMGMU +7 (499) 340 10 14 info@labmgmu.ru 119435, Moscow, Malaya Pirogovskay str. 13-1, floor 4